2023 Q1 Form 10-Q Financial Statement

#000121390023040499 Filed on May 16, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.078M $191.0K
YoY Change 464.4% -13.18%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses -$1.883M $191.0K
YoY Change -1085.86% -13.18%
Operating Profit $1.883M -$191.0K
YoY Change -1085.86%
Interest Expense $100.0K $25.00K
YoY Change 300.0% -50.0%
% of Operating Profit 5.31%
Other Income/Expense, Net $800.0K $6.849M
YoY Change -88.32% 42.69%
Pretax Income $914.0K $6.683M
YoY Change -86.32% 44.34%
Income Tax
% Of Pretax Income
Net Earnings $882.0K $6.683M
YoY Change -86.8% 44.34%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share $0.08 $178.2K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.000K $528.0K
YoY Change -99.43% -62.29%
Cash & Equivalents $3.000K $528.0K
Short-Term Investments
Other Short-Term Assets $206.0K $191.0K
YoY Change 7.85% -52.25%
Inventory
Prepaid Expenses $206.0K
Receivables
Other Receivables
Total Short-Term Assets $209.0K $719.0K
YoY Change -70.93% -60.06%
LONG-TERM ASSETS
Property, Plant & Equipment $5.000M
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $41.00M $300.1M
YoY Change -86.34% 0.03%
Other Assets
YoY Change
Total Long-Term Assets $41.00M $300.1M
YoY Change -86.34% 0.03%
TOTAL ASSETS
Total Short-Term Assets $209.0K $719.0K
Total Long-Term Assets $41.00M $300.1M
Total Assets $41.21M $300.8M
YoY Change -86.3% -0.32%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $11.00K $26.00K
YoY Change -57.69%
Accrued Expenses $828.0K $2.668M
YoY Change -68.97% 1234.0%
Deferred Revenue
YoY Change
Short-Term Debt $1.359M $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.198M $2.694M
YoY Change -18.41% 1247.0%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $12.86M $16.57M
YoY Change -22.41% -38.17%
Total Long-Term Liabilities $12.86M $16.57M
YoY Change -22.41% -38.17%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.198M $2.694M
Total Long-Term Liabilities $12.86M $16.57M
Total Liabilities $15.06M $19.27M
YoY Change -21.85% -28.65%
SHAREHOLDERS EQUITY
Retained Earnings -$14.85M
YoY Change
Common Stock $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$14.85M -$18.45M
YoY Change
Total Liabilities & Shareholders Equity $41.21M $300.8M
YoY Change -86.3% -0.32%

Cashflow Statement

Concept 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income $882.0K $6.683M
YoY Change -86.8% 44.34%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$567.0K -$314.0K
YoY Change 80.57% -34.58%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $264.6M $0.00
YoY Change -100.0%
Cash From Investing Activities $264.6M $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $265.1M $0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -$264.1M 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -$567.0K -314.0K
Cash From Investing Activities $264.6M 0.000
Cash From Financing Activities -$264.1M 0.000
Net Change In Cash -$98.00K -314.0K
YoY Change -68.79% -122.59%
FREE CASH FLOW
Cash From Operating Activities -$567.0K -$314.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
8000 usd
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-39875
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
E9
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
200 Park Avenue
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
32nd Floor
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
New York
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10166
CY2023Q1 dei City Area Code
CityAreaCode
(646)
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
585-8975
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
true
CY2023Q1 us-gaap Cash
Cash
3000 usd
CY2022Q4 us-gaap Cash
Cash
101000 usd
CY2023Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
206000 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
8000 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
209000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
109000 usd
CY2023Q1 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
40996000 usd
CY2022Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
304675000 usd
CY2023Q1 us-gaap Assets
Assets
41205000 usd
CY2022Q4 us-gaap Assets
Assets
304784000 usd
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
11000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
75000 usd
CY2023Q1 us-gaap Notes Payable Current
NotesPayableCurrent
755000 usd
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
785000 usd
CY2023Q1 us-gaap Other Notes Payable
OtherNotesPayable
604000 usd
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
828000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3016000 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
2198000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3876000 usd
CY2023Q1 us-gaap Derivative Liabilities
DerivativeLiabilities
2357000 usd
CY2022Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
467000 usd
CY2023Q1 us-gaap Deferred Compensation Liability Classified Noncurrent
DeferredCompensationLiabilityClassifiedNoncurrent
10500000 usd
CY2022Q4 us-gaap Deferred Compensation Liability Classified Noncurrent
DeferredCompensationLiabilityClassifiedNoncurrent
10500000 usd
CY2023Q1 us-gaap Liabilities
Liabilities
15055000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
14843000 usd
CY2023Q1 gpac Ordinary Shares Subject To Possible Redemption
OrdinarySharesSubjectToPossibleRedemption
3931719 shares
CY2022Q4 gpac Ordinary Shares Subject To Possible Redemption
OrdinarySharesSubjectToPossibleRedemption
30000000 shares
CY2023Q1 us-gaap Temporary Equity Redemption Price Per Share
TemporaryEquityRedemptionPricePerShare
10.42
CY2022Q4 us-gaap Temporary Equity Redemption Price Per Share
TemporaryEquityRedemptionPricePerShare
10.15
CY2023Q1 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
40996000 usd
CY2022Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
304675000 usd
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q1 gpac Common Stock One Value
CommonStockOneValue
1000 usd
CY2022Q4 gpac Common Stock One Value
CommonStockOneValue
1000 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-14847000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-14735000 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-14846000 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-14734000 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
41205000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
304784000 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1078000 usd
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
191000 usd
CY2023Q1 gpac Settlement And Release Of Liabilities1
SettlementAndReleaseOfLiabilities1
2961000 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
1883000 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-191000 usd
CY2023Q1 us-gaap Interest Income Other
InterestIncomeOther
921000 usd
CY2022Q1 us-gaap Interest Income Other
InterestIncomeOther
25000 usd
CY2023Q1 gpac Write Off Contingent Warrants Associated With Shares Redeemed
WriteOffContingentWarrantsAssociatedWithSharesRedeemed
130000 usd
CY2023Q1 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-32000 usd
CY2023Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
2020000 usd
CY2022Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-6849000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
882000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
6683000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-14734000 usd
CY2023Q1 gpac Accretion In Value Of Class A Ordinary Shares Subject To Redemption
AccretionInValueOfClassAOrdinarySharesSubjectToRedemption
1371000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
377000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
882000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-14846000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-25128000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
6683000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-18445000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
882000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
6683000 usd
CY2023Q1 us-gaap Gain Loss On Investments
GainLossOnInvestments
921000 usd
CY2022Q1 us-gaap Gain Loss On Investments
GainLossOnInvestments
25000 usd
CY2023Q1 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-32000 usd
CY2023Q1 gpac Change In Fair Value Of Warrant Liability
ChangeInFairValueOfWarrantLiability
-1890000 usd
CY2022Q1 gpac Change In Fair Value Of Warrant Liability
ChangeInFairValueOfWarrantLiability
6849000 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
198000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-64000 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-109000 usd
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2188000 usd
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-6000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-567000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-314000 usd
CY2023Q1 us-gaap Payments To Acquire Assets Investing Activities
PaymentsToAcquireAssetsInvestingActivities
450000 usd
CY2023Q1 us-gaap Proceeds From Decommissioning Fund
ProceedsFromDecommissioningFund
265050000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
264600000 usd
CY2023Q1 gpac Redemption Of Common Shares
RedemptionOfCommonShares
26068281 shares
CY2022Q1 gpac Redemption Of Common Shares
RedemptionOfCommonShares
26068281 shares
CY2023Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
265050000 usd
CY2023Q1 gpac Repay Sponsor Working Capital Loan
RepaySponsorWorkingCapitalLoan
30000 usd
CY2023Q1 us-gaap Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
949000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-264131000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-98000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-314000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
101000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
842000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
528000 usd
CY2022Q1 gpac Deferred Underwriter Compensation
DeferredUnderwriterCompensation
10500000 usd
CY2022Q1 gpac Offering Costs Included In Offering Costs Payable And Accrued
OfferingCostsIncludedInOfferingCostsPayableAndAccrued
70000 usd
CY2023Q1 gpac Shares Redemption Percentage
SharesRedemptionPercentage
0.87 pure
CY2023Q1 gpac Proceeds From Public Offering
ProceedsFromPublicOffering
300000000 usd
CY2021Q1 gpac Trust Account
TrustAccount
300000000 usd
CY2023Q1 gpac Redemption Price Per Share
RedemptionPricePerShare
10.167
CY2023Q1 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
265050000 usd
CY2023Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
3000000 usd
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2961000 usd
CY2023Q1 us-gaap Interest Expense
InterestExpense
100000 usd
CY2023Q1 gpac Shares Redemption Percentage
SharesRedemptionPercentage
1 pure
CY2023Q1 us-gaap Payments For Proceeds From Deposit On Loan
PaymentsForProceedsFromDepositOnLoan
150000 usd
CY2023Q1 us-gaap Equity Method Investment Aggregate Cost
EquityMethodInvestmentAggregateCost
300000 usd
CY2023Q1 gpac Taxes Payable On Interest Earned Percentage
TaxesPayableOnInterestEarnedPercentage
0.80 pure
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5000001 usd
CY2023Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
10
CY2023Q1 us-gaap Assets Held In Trust
AssetsHeldInTrust
300000000 usd
CY2023Q1 us-gaap Common Stock Shares Held In Employee Trust Shares
CommonStockSharesHeldInEmployeeTrustShares
30000000 shares
CY2023Q1 gpac Dissolution Expenses
DissolutionExpenses
100000 usd
CY2021 gpac Offering Costs
OfferingCosts
16254000 usd
CY2021 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
30354000 usd
CY2023Q1 us-gaap Investments And Cash
InvestmentsAndCash
3000 usd
CY2023Q1 gpac Negative Working Capital
NegativeWorkingCapital
1989000 usd
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11221954 shares
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15566667 shares
CY2023Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Concentration of Credit Risk: </i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company has significant cash balances at financial institutions which throughout the year regularly exceed the federally insured limit of $250,000. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations, and cash flows.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
CY2023Q1 us-gaap Federal Deposit Insurance Corporation Premium Expense
FederalDepositInsuranceCorporationPremiumExpense
250000 usd
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Use of Estimates:</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The preparation of financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statement, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. One of the more significant estimates included in these financial statements is the determination of the fair value of the warrant liability. Such estimates may be subject to change as more current information becomes available and accordingly the actual results could differ significantly from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
CY2023Q1 gpac Total Offering Cost
TotalOfferingCost
17054000 usd
CY2023Q1 gpac Underwriters Discount
UnderwritersDiscount
16500000 usd
CY2023Q1 us-gaap Temporary Equity Stock Issued During Period Value New Issues
TemporaryEquityStockIssuedDuringPeriodValueNewIssues
16254000 usd
CY2023Q1 us-gaap Other Expenses
OtherExpenses
800000 usd
CY2023Q1 us-gaap Other Intangible Assets Net
OtherIntangibleAssetsNet
5000001 usd
CY2023Q1 gpac Permanent Equity Shares
PermanentEquityShares
3931719 shares
CY2022Q4 gpac Permanent Equity Shares
PermanentEquityShares
30000000 shares
CY2021Q4 gpac Permanent Equity Shares
PermanentEquityShares
30000000 shares
CY2021 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
300000000 usd
CY2021 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
14100000 usd
CY2021 us-gaap Temporary Equity Issue Period Increase Or Decrease
TemporaryEquityIssuePeriodIncreaseOrDecrease
300000000 usd
CY2022 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
4675000 usd
CY2022Q4 us-gaap Temporary Equity Aggregate Amount Of Redemption Requirement
TemporaryEquityAggregateAmountOfRedemptionRequirement
304675000 usd
CY2023Q1 gpac Class A Ordinary Shares Redeemed
ClassAOrdinarySharesRedeemed
-265050000 usd
CY2023Q1 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
1371000 usd
CY2023Q1 gpac Ordinary Shares Subject To Redemption Total
OrdinarySharesSubjectToRedemptionTotal
40996000 usd
CY2021Q1 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
30000000 shares
CY2021Q1 gpac Share Purchase Price
SharePurchasePrice
10
CY2023Q1 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
CY2023Q1 gpac Redeemable Warrants
RedeemableWarrants
0.01
CY2023Q1 gpac Ordinary Shares Equals Exceeds
OrdinarySharesEqualsExceeds
18
CY2023Q1 gpac Underwriting Discount Percentage
UnderwritingDiscountPercentage
0.02 pure
CY2023Q1 us-gaap Other Underwriting Expense
OtherUnderwritingExpense
6000000 usd
CY2023Q1 gpac Deferred Underwriting Percentage
DeferredUnderwritingPercentage
0.035 pure
CY2023Q1 gpac Deferred Underwriting Fees Payable
DeferredUnderwritingFeesPayable
10500000 usd
CY2023Q1 gpac Redemption Price Per Share
RedemptionPricePerShare
10.167
CY2023Q1 us-gaap Redeemable Noncontrolling Interest Equity Redemption Value
RedeemableNoncontrollingInterestEquityRedemptionValue
265050166 usd
CY2023Q1 gpac Contingent Redeemable Warrants
ContingentRedeemableWarrants
4344714 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
26068281 shares
CY2023Q1 us-gaap Liability For Catastrophe Claims Carrying Amount
LiabilityForCatastropheClaimsCarryingAmount
130000 usd
CY2023Q1 gpac Founder Share Vesting Description
FounderShareVestingDescription
The Founder Shares are substantially identical to the Class A ordinary shares included in the Units sold in the Public Offering except that the Founder Shares automatically convert into Class A ordinary shares at the time of the initial Business Combination, or at any time prior thereto at the option of the holder, and are subject to certain transfer restrictions, as described in more detail below, and the Founder Shares are subject to vesting as follows: 50% upon the completion of a Business Combination and then 12.5% on each of the attainment of Return to Shareholders (as defined in the agreement) exceeding 20%, 30%, 40% and 50%. Certain events, as defined in the agreement, could trigger an immediate vesting under certain circumstances. Founder Shares that do not vest within an eight-year period from the closing of the Business Combination will be cancelled.
CY2020Q4 gpac Aggregate Loan Amount
AggregateLoanAmount
300000 usd
CY2020Q4 us-gaap Proceeds From Issuance Of Unsecured Debt
ProceedsFromIssuanceOfUnsecuredDebt
1000 usd
CY2022Q3 gpac Principal Amount
PrincipalAmount
2000000 usd
CY2023Q1 us-gaap Loans Payable
LoansPayable
30000 usd
CY2022 gpac Outstanding Principal Balance
OutstandingPrincipalBalance
755000 usd
CY2023Q1 gpac Outstanding Principal Balance
OutstandingPrincipalBalance
785000 usd
CY2023Q1 gpac Unpaid Principal Amount
UnpaidPrincipalAmount
250000 usd
CY2023Q1 gpac Valuations Fair Value
ValuationsFairValue
572000 usd
CY2023Q1 gpac Drawdown Shares
DrawdownShares
377000 shares
CY2023Q1 us-gaap Proceeds From Other Equity
ProceedsFromOtherEquity
377000 usd
CY2023Q1 us-gaap Hedged Asset Fair Value Hedge Cumulative Increase Decrease
HedgedAssetFairValueHedgeCumulativeIncreaseDecrease
32000 usd
CY2023Q1 us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
604000 usd
CY2023Q1 gpac Outstanding Principal Balances
OutstandingPrincipalBalances
345000 usd
CY2022Q3 gpac Extension Promissory Notes Related Party
ExtensionPromissoryNotesRelatedParty
604000 usd
CY2022Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
604000 usd
CY2022Q1 us-gaap Payments To Acquire Assets Investing Activities
PaymentsToAcquireAssetsInvestingActivities
usd
CY2022Q1 us-gaap Proceeds From Decommissioning Fund
ProceedsFromDecommissioningFund
usd
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
CY2022Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
usd
CY2022Q1 us-gaap Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
usd
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
1.5
CY2023Q1 us-gaap Share Price
SharePrice
3.63
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.03 pure
CY2023Q1 gpac Implied Probability Of Merger Successin Shares
ImpliedProbabilityOfMergerSuccessinShares
0.60 pure
CY2023Q1 us-gaap Other Borrowings
OtherBorrowings
300000 usd
CY2023Q1 gpac Additional Borrowing
AdditionalBorrowing
20000 usd
CY2023Q1 us-gaap Sponsor Fees
SponsorFees
25000 usd
CY2023Q1 us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
75000 usd
CY2022Q1 us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
75000 usd
CY2023Q1 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
50000 usd
CY2022Q4 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
0 usd
CY2023Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
15566667 shares
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
11221954 shares
CY2023Q1 gpac Contingent Redeemable Warrants
ContingentRedeemableWarrants
4344714 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
26068281 shares
CY2023Q1 us-gaap Derivative Liabilities
DerivativeLiabilities
2357000 usd
CY2022Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
467000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
CY2023Q1 gpac Deferred Underwriter Compensation
DeferredUnderwriterCompensation
usd
CY2023Q1 gpac Offering Costs Included In Offering Costs Payable And Accrued
OfferingCostsIncludedInOfferingCostsPayableAndAccrued
usd
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2023Q1 us-gaap Fair Value Concentration Of Risk Federal Funds Sold And Securities Borrowed Or Purchased Under Agreements To Resell
FairValueConcentrationOfRiskFederalFundsSoldAndSecuritiesBorrowedOrPurchasedUnderAgreementsToResell
300000000 usd
CY2023Q1 us-gaap Auction Market Preferred Securities Shares Redeemed
AuctionMarketPreferredSecuritiesSharesRedeemed
26068281 shares
CY2023Q1 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
10.167
CY2023Q1 gpac Common Stock Redemption Amount
CommonStockRedemptionAmount
265050000 usd
CY2023Q1 gpac Common Stock In Total
CommonStockInTotal
550000000 shares
CY2023Q1 us-gaap Business Combination Control Obtained Description
BusinessCombinationControlObtainedDescription
The Founder Shares are subject to vesting as follows: 50% upon the completion of a Business Combination and then an additional 12.5% on the attainment of each of a series of certain “shareholder return” targets exceeding 20%, 30%, 40% and 50%, as further defined in the agreement. Certain events, as defined in the agreement, could trigger an immediate vesting under certain circumstances. Founder Shares that do not vest within an eight-year period from the closing of the Business Combination will be cancelled. 
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.01 pure
CY2023Q1 us-gaap Fair Value Investments Entities That Calculate Net Asset Value Per Share Percent Equity Securities
FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerSharePercentEquitySecurities
0.01 pure
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
Global Partner Acquisition Corp II
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
usd
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001831979

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
gpac-20230331_cal.xml Edgar Link unprocessable
gpac-20230331_lab.xml Edgar Link unprocessable
0001213900-23-040499-index-headers.html Edgar Link pending
0001213900-23-040499-index.html Edgar Link pending
0001213900-23-040499.txt Edgar Link pending
0001213900-23-040499-xbrl.zip Edgar Link pending
f10q0323ex31-1_globalpart2.htm Edgar Link pending
f10q0323ex31-2_globalpart2.htm Edgar Link pending
f10q0323ex32-1_globalpart2.htm Edgar Link pending
f10q0323ex32-2_globalpart2.htm Edgar Link pending
f10q0323_globalpart2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
gpac-20230331.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
gpac-20230331_def.xml Edgar Link unprocessable
gpac-20230331_pre.xml Edgar Link unprocessable
f10q0323_globalpart2_htm.xml Edgar Link completed